Non Hodgkin Lymphoma

• CLINICAL_TRIALS trial_result · 2021-10-13
  Clinical Trial Update: Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma [Phase 1, Phase 2]

  Phase 1/2 trial evaluating venetoclax, lenalidomide, and rituximab in relapsed/refractory mantle cell lymphoma (a relapsed non-Hodgkin lymph…

• CLINICAL_TRIALS trial_result · 2021-08-02
  Clinical Trial Update: A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma [Phase 2]

  Phase 2 clinical trial evaluating CD19/22 CAR-T cells combined with a PD-1 inhibitor in relapsed/refractory B-cell lymphoma.

• CLINICAL_TRIALS trial_result · 2021-05-18
  Clinical Trial Update: Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  A Phase 1/2 trial investigated outpatient administration of R-DHAP in relapsed or refractory non-Hodgkin lymphoma; status completed.

• CLINICAL_TRIALS trial_result · 2019-04-16
  Clinical Trial Update: CAR-T for R/R B-NHL [Phase 2]

  A Phase 2 clinical trial update on CAR-T therapy targeting CD19/CD20/CD22/CD30 for relapsed or refractory non-Hodgkin lymphoma.

• CLINICAL_TRIALS trial_result · 2018-10-25
  Clinical Trial Update: Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

  Phase 2 clinical trial investigating azacitidine and rituximab-GDP immunochemotherapy for relapsed/refractory diffuse large B-cell lymphoma …

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.